William Blair & Company
ADVM

William Blair & Company’s Adverum Biotechnologies ADVM Stock Holding History

William Blair & Company’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,444
Closed -$585K – 2196
2015
Q1 		$585K Buy
+1,444
New +$610K ﹤0.01% 1673

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

William Blair & Company's ADVM Position: Q2 2015 in Review

William Blair & Company sold out of Adverum Biotechnologies (ADVM) in Q2 2015, closing a stake of 1,444 shares — an estimated $585K sold.

William Blair & Company first reported a position in ADVM in Q1 2015 and held it in 1 quarter. The position peaked at $585K in Q1 2015. 96 funds tracked by Wall St. Rank hold ADVM as of Q2 2015.

  • William Blair & Company reported no remaining Adverum Biotechnologies position as of Q2 2015 after selling out during the quarter.
  • William Blair & Company sold 1,444 Adverum Biotechnologies shares in Q2 2015, an estimated $585K.
  • William Blair & Company first reported a position in Adverum Biotechnologies in Q1 2015 and held it in 1 quarter.
  • William Blair & Company's Adverum Biotechnologies position peaked at $585K in Q1 2015.
  • 96 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2015.

Based on William Blair & Company's 13F filing for Q2 2015, filed 3 Aug 2015.